CareCloud, Inc. filings document operating results, Regulation FD presentation materials, governance actions, and capital-structure disclosures for a healthcare technology and revenue cycle management company. The records cover common stock, preferred-stock dividend and security matters, credit facility events, and formal updates tied to financial performance.
CareCloud’s proxy and current reports also disclose shareholder voting matters, bylaw amendments, board and audit committee composition, Nasdaq compliance items, and cybersecurity incident reporting. These filings frame the company’s Healthcare IT and Medical Practice Management activities alongside risk, governance, and public-company reporting obligations.
CareCloud, Inc. files its annual report describing its technology-enabled revenue cycle management, cloud software and expanding generative AI solutions for U.S. healthcare providers. The company relies heavily on offshore operations in Pakistan and Sri Lanka, where roughly 3,300 staff support its cost advantage.
As of June 30, 2025, non‑affiliate common equity had an aggregate market value of about $85.1 million, and at March 6, 2026 there were 42,492,949 common shares outstanding. The filing highlights extensive business, cybersecurity, regulatory and macro risks, including past suspension and later resumption of preferred dividends, ongoing arrears, and dilution from a March 2025 conversion of most Series A preferred into common stock.
CareCloud, Inc. filed a current report describing several updates. The company issued an earnings press release and an accompanying slide presentation on March 12, 2026, which are included as exhibits and provide details on its recent operating and financial performance.
On March 10, 2026, director A. Hadi Chaudhry resigned from the Board, effective immediately. His resignation is intended to help the company regain compliance with Nasdaq Listing Rule 5605, which requires a majority-independent board. The company states his departure did not arise from any disagreement over operations, policies, or practices.
CareCloud director Lawrence S. Sharnak reported an equity award vesting and share issuance. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of CareCloud common stock at a price of $0. According to the filing, these restricted stock units and the resulting shares were granted under the company’s Amended and Restated Equity Incentive Plan without payment by Sharnak.
Following the transaction, Sharnak directly owned 127,750 shares of common stock and 26,250 restricted stock units. This reflects routine compensation-related activity rather than an open-market purchase or sale.
CareCloud, Inc. director Cameron Munter reported a routine equity compensation vesting. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a price of $0 per share, under the company’s Amended and Restated Equity Incentive Plan.
After this conversion, Munter directly beneficially owned 202,750 shares of CareCloud common stock and 26,250 restricted stock units. The transaction involved no cash payment by the reporting person and reflects standard compensation-based vesting rather than an open‑market purchase or sale.
CareCloud, Inc. director Anne Busquet reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by her.
After this equity award vesting, she directly holds 295,138 shares of CareCloud common stock and 26,250 derivative securities in the form of restricted stock units.
CareCloud, Inc. director Bill Korn reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by Korn.
After this transaction, Korn beneficially owns 211,633 shares of CareCloud common stock directly and 26,250 restricted stock units, reflecting his ongoing equity-based compensation as a director.
CareCloud, Inc. director Bill Korn reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Korn. Following this transaction, he directly owned 204,133 shares of common stock and 33,750 restricted stock units.
CareCloud, Inc. director Anne Busquet reported a routine equity award vesting and conversion. On January 31, 2026, 6,250 restricted stock units vested and converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Busquet.
After this transaction, she directly holds 287,638 shares of common stock and 33,750 restricted stock units, reflecting ongoing participation in CareCloud’s long‑term incentive program rather than an open‑market purchase or sale.
CareCloud director Lawrence Steven Sharnak reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of CareCloud common stock at a price of $0 per share under the company’s Amended and Restated Equity Incentive Plan.
After this transaction, Sharnak directly owned 120,250 shares of common stock and 33,750 restricted stock units. The award vested without cash payment by the reporting person, reflecting compensation delivered in company equity rather than cash.
CareCloud, Inc. director Cameron Munter reported the vesting and conversion of restricted stock units into common stock. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under CareCloud’s Amended and Restated Equity Incentive Plan, without payment by Munter.
After this transaction, Munter directly owned 195,250 shares of CareCloud common stock and 33,750 restricted stock units. The filing reflects equity-based compensation vesting rather than an open‑market purchase or sale.